Charles River Laboratories (CRL) Reaffirms 2026 Guidance at Upper End, Sets 2030 Targets

Charles River Laboratories reaffirmed its 2026 revenue and non-GAAP EPS guidance at the upper end of prior ranges, citing continued favorable demand. At its investor day, the company introduced long-term targets through 2030 including 5%-7% organic revenue CAGR and ~24% non-GAAP operating margin. It expects to generate over $300 million in cumulative savings from 2027 to 2030 under its 'Create the Future' program.